Kornimate/medical-research-clean huggingface dataset:
validation of a model for predicting anastomotic leakage

Conditions: Gastric Cancer

Summary: this study will validate a machine learning model for predicting anastomotic leakage of esophagogastrostomy and esophagojejunostomy.

anastomotic leakage is a fatal complication after total and proximal gastrectomy in gastric cancer patients. identifying patients with high-risk of al is important for guiding the surgeons' decision making, such as a more rigorous anastomotic operation， placing a jejunal feeding tube and dual-lumen flushable drainage catheter. we have developed a high-performance machine learning model based on 1660 gastric cancer patients, which showed good discrimination of anastomotic leakage. hence, this multi-center prospective study will validiate the usability of the model for predicting anastomotic leakage in gastric cancer patients who receive total and proximal gastrectomy.

Eligibility criteria:
inclusion criteria: inclusion criteria: 1. aged older than 18 years and younger than 85 years. 2. primary gastric adenocarcinoma confirmed by preoperative pathology. 3. expected curative resection via total or proximal gastrectomy. 4. american society of anesthesiologists (asa) class i, ii, or iii. 5. written informed consent. exclusion criteria: 1. pregnant or breastfeeding women. 2. severe mental disorder or language communication disorder. 3. other surgical procedures of gastrectomy is performed. 4. interrupted of surgery for more than 30 minutes due to any cause. 5. malignant tumors with other organs

Keywords: machine learning anastomotic leakage total and proximal gastrectomy
slmap and epo genetic polymorphism in diabetic retinopathy

Conditions: Diabetic Retinopathy

Summary: a case-control study to assess the association between the risk of diabetic retinopathy in egyptians and genetic polymorphism of both epo and slmap genes.

traditional environmental risk factors, such as glycemic control and duration of diabetes, failed to fully explain why some individuals remain protected while others progress to severe diabetic retinopathy. several studies suggest variations in diabetic retinopathy prevalence depending on racial background and genetic polymorphism.

Eligibility criteria:
inclusion criteria: * age \>30-60 * type 2 dm * duration of diabetes from 5-10 years * egyptian patients exclusion criteria: * other ophthalmic diseases not related to diabetes
chidamide combined with pecm in relapsed or refractory peripheral t-cell lymphoma (ptcl)

Conditions: Peripheral T-cell Lymphoma

Summary: to observe the efficacy and safety of chidamide combined with prednisone, cyclophosphamide, etoposide and methotrexate in relapsed or refractory ptcl.

prednisone, cyclophosphamide, etoposide, and methotrexate regimens are derived from a "metronidazole, etoposide, procarbazine and cyclophosphamide (pepc) regimen" regimen that differs from the traditional "maximal tolerance "chemotherapy, and the use of low-dose chemotherapy, frequent drug therapy, the purpose is to anti-angiogenesis and reduce drug resistance. at present, the program in our treatment of relapsed or refractory ptcl patients effective, safe and controllable, but also look forward to other joint treatment, so as to achieve better curative effect. to provide new treatment options for such patients.

Eligibility criteria:
inclusion criteria: 1. histopathologically confirmed peripheral t-cell lymphoma (ptcl) patients; 2. patients who have had at least one systemic treatment (including chemotherapy, hematopoietic stem cell transplantation, etc.) who have not remission or relapsed after remission; 3. for various reasons can not be hematopoietic stem cell transplantation in patients; 4. the age of 18-75 years old, male, female open; 5. ecog (eastern cooperative oncology group) physical scoring 0-1 points; 6. absolute value of neutrophil≥1.5 × 109 / l, platelet≥90 × 109 / l, hemoglobin≥90g / l; 7. the expected survival time ≥ 3 months; 8. no radiotherapy, chemotherapy, targeted therapy or hematopoietic stem cell transplantation were performed within 4 weeks prior to enrollment. 9. voluntary signature of written informed consent. exclusion criteria: 1. pregnancy, breastfeeding women and unwilling to take contraceptive measures of reproductive age patients; 2. b-mode ultrasonography showed that the width of end-diastolic pericardial dark area was ≥10mm; 3. patients receiving organ transplants; 4. patients receiving symptomatic treatment of pre-bone marrow toxicity within 7 days prior to enrollment; 5. patients with active bleeding; 6. liver function abnormalities (total bilirubin\> 1.5 times the upper limit of normal, alt( alanine aminotransferase) / ast (aspartate aminotransferase)\> 2.5 times the upper limit of normal or hepatic involvement of alt / ast\> 5 times the upper limit of normal), renal dysfunction creatinine\> 1.5 times the upper limit of normal), electrolyte abnormalities; 7. persons with mental disabilities / those who can not obtain informed consent; 8. patients with drug abuse and long-term alcohol abuse that may affect the evaluation of test results; 9. the investigators determined that they were not fit to participate in the trial.

Keywords: relapsed or refractory peripheral t-cell lymphoma combination therapy
tranexamic acid in debridement surgery of burns on the volume of bleeding in transfusion requirements

Conditions: Burns

Summary: tranexamic acid in debridement surgery of burns on the volume of bleeding in transfusion requirements

a randomized, double-blind, prospective trial was conducted to establish the effect of intraoperative tranexamic acid in the early surgical debridement of severe burns. the study was carried out between the months of january 2022 and december 2023.

Eligibility criteria:
inclusion criteria: 1. first-time patients undergo surgical debridement of their burns. 2. a burn percentage of 10-30% of burned body surface area 3. patients over 18 years of age 4. patients under 40 5. imss beneficiaries exclusion criteria: 1. burned patients with previous surgical debridement. 2. patients with co-morbids. 3. patients with a history of drug hypersensitivity. 4. patients with kidney disease.

Keywords: burns
the effectiveness of continuous glucose monitoring in diabetes treatment for infants and young children

Conditions: Diabetes Mellitus, Type I

Summary: the purpose of this study is to see if the use of a real-time glucose sensor improves diabetes control in young children (less than 4 years old) with type i diabetes when they are initiated on insulin pump therapy.

a randomized controlled clinical trial involving patients 0-3 yrs old with type 1 diabetes. after successful screening the subjects will be randomized into one of two groups: a csii group alone and a csii group + real time sensor augmentation group (rtsa) group. the csii group will serve as the control for the csii+rtsa group. the trial will last for one year.

Eligibility criteria:
inclusion criteria: * children less than 4 years of age with type i diabetes for at least 3 months exclusion criteria: * children greater than 4 years of age * monogenic diabetes

Keywords: diabetes mellitus, type i children insulin pump therapy continuous glucose monitor
the effect of brief bodyweight exercise on acute glycemic control in healthy inactive adults

Conditions: Exercise

Summary: this study will investigate whether an 11-minute bodyweight exercise session can improve short-term glycemic control. glycemic control refers to the process of how the body regulates blood sugar. the process can be measured in different ways. this study will use a small device called a continuous glucose monitor to measure changes in glucose levels over a 24-hour period. participants will complete two trials and the investigators will compare glycemic control after the exercise session and a control period that does not involve exercise. food intake will be controlled such that each participant will consume the same diet in both conditions. this study will help determine whether a single session of bodyweight exercise affects glycemic control.

this study will investigate whether an 11-minute bodyweight exercise session can improve short-term glycemic control. glycemic control will be assessed using continuous glucose monitoring for 24 hours following exercise or a control condition that does not involve exercise. the exercise and control periods will be directly supervised by a study investigator. participants will complete two trials in a randomized, crossover manner separated by 7 days. food intake will be controlled such that each participant will consume the same diet over the 24-hour period of measurement in both conditions. standardized meals will be provided to participants prior and following the exercise and control conditions. this study will determine whether a single session of bodyweight exercise affects glycemic control as primarily assessed by mean 24-hour glucose.

Eligibility criteria:
inclusion criteria: * inactive, defined as not meeting the physical activity targets in the canadian 24-hour movement guidelines for adults. * deemed able to safely participate in physical activity and exercise, as determined by the canadian society for exercise physiology (csep) get active questionnaire prescreening tool. exclusion criteria: - experiencing a condition that might preclude safe participation in physical activity and exercise, as determined by answering "yes" to any question on page 1 of the csep get active questionnaire.

Keywords: glycemic control
caregiver as navigator: develop skills online (can-do)

Conditions: Dementia

Summary: this study is designed to learn more about ways to promote caregiver mastery online. 270 dementia family caregivers will be enrolled and randomized to take the can-do online course immediately or after a waiting period. they will participate in interviews before and after the course; total time of study participation is 6 months.

family members and friends are the core of the uncoordinated system of care that tenuously maintains persons living with dementia in their community settings and delays their placement into more costly settings of institutional care, providing more contributed and out of pocket care support than medicare and medicaid combined. the can-do program fills a significant gap in caregiver psychoeducation programming by focusing not principally on day-to-day care management but on the many substantial system navigation tasks that caregivers assume. supported by preliminary efficacy data, can-do will employ state-of-the art asynchronous interactive learning methods to enhance caregivers' mastery of skills and confidence to navigate healthcare and other (legal, financial, social service, and family) systems that are crucial to the continued community living of persons affected with dementia illnesses. this study will enroll 270 dementia family caregivers who will be randomized to take the can-do course immediately or after a waiting period. they will participate in interviews before and after the course; total time of study participation is 6 months.

Eligibility criteria:
inclusion criteria: * family member or friend providing at least 4 hours per week of informal care for a community-dwelling person living with adrd * 18 years or older * has internet access * does not have to co-reside with the individual * understands, speaks, and reads english exclusion criteria: * family caregiver plans to move care recipient to an institutional setting within the next six months * care recipient currently enrolled in hospice

Keywords: caregiver dementia
the use of an oral mixture of arginine, glutamine and beta-hydroxy-beta-methylbutyrate for treatment of pressure ulcers

Conditions: Pressure Ulcers Stage III; Pressure Ulcer, Stage IV

Summary: to investigate whether an oral nutritional supplement of a mixture of arginine, glutamine and hmb for a maximum period of four weeks is more beneficial than the standard dietary approach to the healing of pressure ulcers, and to examine whether the use of it can reduce admissions and length of hospitalizations for these patients.

all patients would be assessed by a dietitian to ensure them receiving nutritional support of at least 30 kcal/kg/day and of at least 1.2 g/kg/day of protein regardless of feeding method. during the study period, vitamin c and zinc supplement would not be given. nutritional supplement other than that provided by the dietitian to meet the energy and protein requirement would not be given. the pressure ulcers would be cared according to the "basic nursing standards for patient care: wound dressing - version 5" published by the hospital authority head office. the treatment group would also be given 2 sackets of a mixture of arginine, glutamine and hmb (abound) every day for a maximum period of 4 weeks, either orally or via enteral feeding.

Eligibility criteria:
inclusion criteria: 1. inpatients of medical and geriatric wards of olmh and wtsh 2. aged 18 and older with stage iii - iv lesions 3. patients fed orally or through feeding tubes were included exclusion criteria: 1. patients with history of using the nutritional supplement (abound) in previous three months 2. patients with cellulitis, wounds with purulent discharge or osteomyelitis or sepsis 3. patients requiring protein restriction 4. patients with poorly controlled diabetes mellitus (latest hba1c \> 8.5) (healing process may be affected 5. patients under palliative care
breathe: an efficacy-implementation with listening sessions

Conditions: Asthma

Summary: listening sessions: the research team will collect qualitative data from the listening sessions (focus groups) using a semi-structured iterative focus group guide.

the trial will be informed by 4-8 listening sessions (research focus groups) with 4-8 adults with asthma at each of four sites (n=32). the trial will also include interviews with approximately 1-2 providers and 1-2 administrators at each site (n=8-16). adults with asthma and providers/administrators will participate in pre-trial listening sessions (focus groups) prior to recruiting for other phases in this project. they will share their experience with asthma and clinical research. this will aid in gaining the identification of possible barriers to participation and will provide the opportunity for the patients and providers/administrators to identify which of the planned outcomes they consider to be most meaningful. after obtaining informed consent from participants, the research team will collect demographic and diagnosis information, administer surveys and conduct listening sessions. the research team will collect demographic information and administer questionnaires to characterize the participants. these include: demographic form, asthma history (patient), asthma history (family), asthma control questionnaire, shared decision making questionnaire, medication adherence record scale (preventer), conventional and alternative management for asthma (patient), conventional and alternative management for asthma (family), asthma quality of life questionnaire, newest vital sign, and short assessment of health literacy. pre-trial listening sessions: one 2-hour session. providers/administrators will participate in one 30-minute session interview. this pre-trial is an informative research that will help design an rct with masking and allocation in the future.

Eligibility criteria:
inclusion criteria: 1. be adults (\> 18 years of age or emancipated) 2. self-report 'black' race (african american, african, caribbean, west indian, multi-racial \[black and one or more additional races\]); identify their ethnicity as hispanic or non-hispanic 3. have clinician-diagnosed asthma 4. receive asthma care at a partner federally-qualified health center (fqhc) exclusion criteria: 1. non-english speaking 2. serious mental health conditions that preclude completion of study procedures or confound analyses 3. participation in a listening session inclusion criteria (provider/administrator): providers who manage a panel of adult asthma patients (i.e., eligible for randomization in the trial) and administrators at that site will be recruited to participate in the interviews.
the effects of plantar flexion training in people with chronic stroke

Conditions: Stroke; Hemiplegic Gait

Summary: this study consists of three phases that aim to develop an exercise intervention to promote maximal activation of ankle plantar flexors in the paretic lower extrimty (le) in order to restore a more normalized gait pattern in chronic stroke survivors. the aim of the first phase is to determine if there are differences between standing on different levels of inclination on plantar flexion activation during forward movement of the contralateral le in adults with chronic with stroke. the aim of second phase is to determine if there are differences between different percentages of weight bearing on the paretic le on plantar flexion activation during forward movement of the contralateral le in adults with chronic stroke. the aim of the third phase is to determine if there are differences between a 4-week plantar flexion training intervention and conventional physical therapy.

description of arms: this study has three phases. the first phase is performed in a cross-over fashion. participants will stand on two different incline angles on the paretic le and simultaneously move a small skateboard forward with the non-paretic le. the testing order for the two different incline angles will be randomized, and all participants will be required to complete both incline angle conditions within a single test session. the second phase will also be performed in a cross-over fashion. participants will stand with three different percentages of body weight on their paretic le while moving the skateboard forward with the non-paretic le. the testing order for the three body weight percentages will be randomized. all participants will be required to complete all three body weight conditions within a single test session. in the third phase, participants will be randomized to either a control 4-week exercise intervention (conventional physical therapy) or a 4-week experimental exercise intervention (plantar flexion training). both the control and exerimental arms will complete over-ground multi-directional gait training and home exercise.

Eligibility criteria:
inclusion criteria: * must be able to perform five times sit to stand test without the use of upper extremities * must have 10 degrees of passive ankle dorsiflexion measured in standing * must be able to walk with supervision level assistance with no assistive device exclusion criteria: * currently receiving physical therapy * history of orthopedic ankle instability * lacking knee extension to neutral * unable to understand english * unable to follow multi-step commands * history of orthopedic pathology that prevents completion of experimental condition * pain with weight bearing on paretic le * received botox to the plantar flexors within the last three months or phenol injections within the last six months * walk with a longer nonparetic step length than paretic step length

Keywords: stroke rehabilitation walking limitations gait rehabilitation
reward mechanisms in obesity

Conditions: Obesity

Summary: the study aims to investigate the effects of 3.0 mg of liraglutide on reward brain circuits in human obesity and to better understand its effects on weight loss (in patients without diabetes). according to the study protocol, 70 obese patient will be evaluated at baseline and at 16-week (end of study) after daily subcutaneous injections of saxenda® (liraglutide 3.0 mg) or placebo by pen injector. all participants will first undergo a functional magnetic resonance imaging (fmri) session while being presented with gustatory stimuli. second, participants will complete behavioural tasks (i.e., liking versus wanting, in the scanner) and questionnaires aiming at teasing apart reward mechanisms and emotional skills (e.g., emotional regulation ability) associated with food intake. third, metabolic parameters and hormones involved in appetite regulation will be assessed and studied in relation to fmri. these measurements will be repeated after 16 weeks in obese individuals. the control group of normal body weight individuals will be evaluated once at baseline.


Eligibility criteria:
inclusion criteria: * bmi ≥ 30 kg/m2 and \< 40 kg/m2 * right-handed * current non-smokers * with stable body weight (\<5% reported change during the previous 3 months) exclusion criteria: * history of any psychiatric, neurological, cardiovascular, renal or liver disease, malignancies, type 1 and type 2 diabetes mellitus * use of centrally acting medication, glucocorticoides, insulin, orlistat * any substance abuse * food allergies * deficits of smell and taste * history of pancreatitis * family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma * pregnancy * contraindications for fmri

Keywords: glp-1 fmri
hyperfibrinogenemia after major trauma

Conditions: Major Trauma

Summary: assessment of the evolution of fibrinogen plasma level within the first ten days after major trauma in order to determine prevalence of hyperfibrinogenemia (fg \> 4 g/l) and its time to onset.

in this study, investigators daily investigate fibrinogen plasma levels and fibrinogen antigen in severe trauma patients (injury severity score \> 15) within the first ten days. investigators then modelize hyperfibrinogenemia profiles according to severity of injuries and physiopathologic mechanisms. finally, investigators determine predisposing risk factors to develop hyperfibrinogenemia and assess the impact of fibrinogen replacement therapy in initial phase of management of major trauma.

Eligibility criteria:
inclusion criteria: * patients older than 18 years old. * polytrauma with iss score \> 15 * hospitalized patients in reanimation unit \< 4h after trauma * informed consent exclusion criteria: * patients in another study * pregnant or lactating women

Keywords: fibrinogen level hyperfibrinogenemia trauma thrombosis risk
screening protocol to determine eligibility for studies of the chemokine coreceptor 5 (ccr5) antagonist gw873140

Conditions: HIV Infection

Summary: the purpose of this study is to determine eligibility for one of three treatment studies of the ccr5 antagonist gw873140 or an observational study without gw873140. no investigational treatment will be administered through this study.


Eligibility criteria:
inclusion criteria: * hiv-infected. * screening viral load at least 5000copies/ml. * total prior antiretroviral experience of at least 3 months and documented resistance to at least one drug in each of the following classes: nucleoside reverse transcriptase inhibitors (nrti), non-nucleoside reverse transcriptase inhibitors (nnrti), and protease inhibitors (pi), stable antiretroviral regimen (or no antiretroviral treatment) for at least 4 weeks before screening. * able to receive a ritonavir-boosted protease inhibitor during treatment studies. * women of childbearing potential must use specific forms of contraception. exclusion criteria: * acute laboratory abnormalities. * history of pancreatitis or hepatitis, hepatitis b or hepatitis c coinfection, or any chronic liver disease. screening liver function tests will be used to determine eligibility. * changes to antiretroviral therapy from 4 weeks prior to screening until day 1 of treatment or observational studies. * pregnancy or breastfeeding women. * recent participation in an experimental drug trial. * prior use of a ccr5 or cxcr4 antagonist. * significant ecg abnormalities or significant history of active pancreatitis, hepatitis, opportunistic infections, malabsorption disorders, cancer, or severe illness. * current use of certain medications may exclude participation in this study. * additional qualifying criteria and laboratory test requirements to be assessed by study physician.

Keywords: hiv-1 gw873140 ccr5 antagonist experienced